Andere Sprachen Genprex, Inc.

Aktien

A3E3Z3

US3724462037

GNPX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 21.06.2024			% 5 Tage	% 1. Jan.
2,02 ^USD	-1,46 %		-6,91 %	-78,04 %

15.05.	Genprex, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
14.05.	Genprex verabreicht ersten Patienten in der klinischen Studie Acclaim-3 zur Immunogen-Therapie Reqorsa in Kombination mit Tecentriq zur Behandlung von kleinzelligem Lungenkrebs	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Genprex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer	14.05.
Genprex, Inc. Appoints Jose A. Moreno Toscano as Chairman of the Board of Directors	13.05.
Genprex, Inc Announces Executive Changes	09.05.
Genprex, Inc Announces Executive Changes	09.05.
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting	10.04.
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System	03.04.
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer	03.04.
Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System	02.04.
Genprex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Genprex Closes $6.5 Million Registered Direct Offering of Shares, Accompanying Warrants	22.03.
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules	20.03.
Genprex Launches $6.5 Million Securities Offering; Shares Fall	19.03.
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers	13.03.
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers	12.03.
Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers	12.03.
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting	07.03.
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators	08.02.
Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators	07.02.
Genprex to Present at Upcoming BIO CEO and Investor Conference	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Genprex, Inc.

Aktien

A3E3Z3

US3724462037

GNPX

Andere Sprachen

Filter